Engineered ZFP36-overexpressing AC16 cell-derived extracellular vesicles attenuate ferroptosis-related endothelial injury and functionalize NiTi vascular interfaces
Colloids and Surfaces B: Biointerfaces
Cite this paper
Plain citation
Demin Li, Yachen Hou, Yang Lu, Pengchong Du, Ge Zhang, Yan Lv, Ke Hu, Rilige Su, Bolin Jiao, Yangyang Wu, Yujia Wang, Jinying Zhang, Junnan Tang. Engineered ZFP36-overexpressing AC16 cell-derived extracellular vesicles attenuate ferroptosis-related endothelial injury and functionalize NiTi vascular interfaces. Colloids and Surfaces B: Biointerfaces. 2027;270:116261. https://doi.org/10.1016/j.colsurfb.2026.116261
Author evidence note
Principal findings
Vesicles released by ZFP36-overexpressing AC16 cells protected RSL3-challenged human umbilical vein endothelial cells: viability and mitochondrial membrane potential improved, while oxidative stress declined. Direct myocardial administration also improved cardiac function and reduced fibrosis in a mouse infarction model.
Vascular-interface contribution
ZFP36-engineered vesicles were immobilized on polydopamine/hyaluronic-acid-modified NiTi (NPH). The study used nanoparticle tracking analysis (NTA) to measure particle concentrations in the remaining suspension and three PBS washes. It subtracted the recovered particle count from the initial input count, then divided by that input count to estimate 72.80% ± 0.83% loading (mean ± SD, n=3). Over 14 days in PBS at 37 °C, it measured released particles by NTA after collecting and replacing the medium at each time point. Cumulative release was expressed relative to the estimated number initially immobilized. Under RSL3, human umbilical vein endothelial cells (HUVECs) were cultured directly on bare NiTi, NPH without vesicles, NPH with control vesicles and NPH with engineered vesicles. The direct-contact assay also included bare NiTi without RSL3. Live/Dead viable-cell percentages and the oxidized-to-reduced C11-BODIPY fluorescence ratio were measured under these direct-contact conditions. The separate rat femoral-artery injury model compared bare, NPH and engineered-vesicle filaments. At 14 days, the rat study assessed H&E morphology and positive-area staining for CD31, TNF-alpha, OPN, alpha-SMA and 4-HNE. The engineered-vesicle filaments supported endothelial recovery and reduced local inflammatory and lipid-peroxidation-associated signals.
Research use
The cell challenge addresses endothelial protection; the mouse infarction model tests intramyocardial delivery; the rat injury model tests the local vascular interface. Figure 4 reports n=6 for echocardiographic measurements at baseline and 21 days and n=5 for the fibrosis endpoint. The study states that its data are available on request.
Publication chronology
PubMed records electronic publication on 15 October 2026. The assigned Crossref print record is volume 270, article 116261, February 2027; formal citation exports use 2027. These dates describe one DOI and one study, not two versions of the evidence.
Evidence scope and limitations
Author-maintained explanation of the published preclinical extracellular-vesicle and vascular-interface study. The full article supports separate cell, mouse infarction, and rat arterial-injury experiments.
- The repair results are preclinical. The 14-day particle-release measurement is an in vitro PBS assay, separate from the rat tissue response.
Provenance
- Published experimental article — Published full text, reviewed from the supplied author copy. Colloids and Surfaces B: Biointerfaces 270 (2027), 116261, pp. 1–13; Sections 2.6–2.12 and 3.3–3.6, Figures 3–6 and Data availability.
- Indexed study abstract and author metadata — PubMed XML abstract and bibliographic metadata; original paraphrase above. PMID 42896257, Abstract, AuthorList, ArticleDate and ArticleIdList.
- Publisher-deposited citation record — Crossref bibliographic metadata. DOI 10.1016/j.colsurfb.2026.116261, published-print, volume and article-number.
Source review: 2026-11-04.